Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

Katja Sockel, Annika Neu, Maren Goeckenjan, Markus Ditschkowski, Inken Hilgendorf, Nicolaus Kröger, Francis A. Ayuk, Friedrich Stoelzel, Jan Moritz Middeke, Matthias Eder, Wolfgang Bethge, Jürgen Finke, Hartmut Bertz, Guido Kobbe, Martin Kaufmann, Uwe Platzbecker, David Beverungen, Christoph Schmid, Malte von Bonin, Katharina Egger-Heidrich, Lisa Heberling, Karolin Trautmann-Grill, Raphael Teipel, Gesine Bug, Johanna Tischer, Alessia Fraccaroli, Matthias Fante, Daniel Wolff, Thomas Luft, Julia Winkler, Kerstin Schäfer-Eckart, Christof Scheid, Udo Holtick, Stefan Klein, Igor Wolfgang Blau, Andreas Burchert, Gerald Wulf, Justin Hasenkamp, Rainer Schwerdtfeger, Stephan Kaun, Christian Junghanss, Friederike Wortmann, Susann Winter, Helga Neidlinger, Catrin Theuser, Jan Beyersmann, Martin Bornhaeuser, Sandra Schmeller, Johannes Schetelig

Blood (2024) 144 (14): 1532–1542.

https://doi.org/10.1182/blood.2024024342

Published: 2024

Includes: Supplemental data

Journal Articles

Results of the Astral Study: A Prospective Phase II Clinical Study of the German Lymphoma Alliance to Assess the Efficacy and Toxicity of High-Dose Chemotherapy Followed By Allogeneic Stem Cell Transplantation As Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma

Bertram Glass, Bettina Altmann, Matthias Stelljes, Georg Lenz, Julia Marx, Justin Hasenkamp, Frank P. Kroschinsky, Anna Ossami Saidy, Peter Dreger, Lutz Peter Hermann Mueller, Inken Hilgendorf, Gerald Illerhaus, Guido Kobbe, Roland Schroers, Katrin Linke, Carsta Koehler, Norbert Schmitz, Marita Ziepert, Pearl van Heteren

Blood (2023) 142 (Supplement 1): 231.

https://doi.org/10.1182/blood-2023-173179

Published: 2023

Journal Articles

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Blood (2022) 140 (Supplement 2): LBA-3.

https://doi.org/10.1182/blood-2022-171733

Published: 2022

Journal Articles

Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Katja Sockel, Sandra Frank, Annika Neu, Markus Ditschkowski, Inken Hilgendorf, Mareen Goeckenjan, Friedrich Stoelzel, Jan Moritz Middeke, Nicolaus Kröger, Francis A. Ayuk, Matthias Eder, Wolfgang Bethge, Jürgen Finke, Hartmut Bertz, Guido Kobbe, Martin Kaufmann, Uwe Platzbecker, David Beverungen, Christoph Schmid, Malte von Bonin, Katharina Egger-Heidrich, Lisa Heberling, Karolin Trautmann-Grill, Raphael Teipel, Gesine Bug, Johanna Tischer, Alessia Fraccaroli, Barbara Holler, Daniel Wolff, Thomas Luft, Wolf Roesler, Kerstin Schäfer-Eckart, Sabine Dressler, Christof Scheid, Udo Holtick, Stefan Klein, Igor Wolfgang Blau, Andreas Burchert, Gerald Wulf, Justin Hasenkamp, Rainer Schwerdtfeger, Stephan Kaun, Christoph Wittke, Friederike Wortmann, Helga Neidlinger, Martin Bornhaeuser, Johannes Schetelig, on Behalf of the German Cooperative Transplant Study Group

Blood (2022) 140 (Supplement 1): 10563–10565.

https://doi.org/10.1182/blood-2022-162673

Published: 2022

Journal Articles

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Blood (2022) 140 (4): 349–358.

https://doi.org/10.1182/blood.2021015209

Published: 2022

Includes: Supplemental data

Journal Articles

Minimum Tolerable Interval of Radioimmunotherapy and Autologous Stem Cell Transplantation after High-Dose Chemotherapy for Relapsed or Refractory Aggressive B Cell Non-Hodgkin-Lymphoma Provides Excellent Disease Control

Justin Hasenkamp, MD, Georg Hess, MD, Bernd Hertenstein, MD, Mathias Witzens-Harig, MD, Lutz Uharek, MD, Martin Gramatzki, MD, Michael Pfreundschuh, Gerald Wulf, MD, Lorenz H. Truemper, MD PhD, Norbert Schmitz, MD, Bertram Glass, MD

Blood (2014) 124 (21): 3986.

https://doi.org/10.1182/blood.V124.21.3986.3986

Published: 2014

Journal Articles

Combination of Lenalidomide and R-DHAP for Treatment of Relapsed and Refractory Aggressive B-NHL

Bertram Glass, MD, Anke Goerlitz, Sebastian Pfeiffer, Maike Nickelsen, MD, Andreas Huettmann, MD, Justin Hasenkamp, MD, Lorenz H. Truemper, MD PhD, Martin Dreyling, Michael G Kiehl, MD, Hans Salwender, MD, Norbert Schmitz, MD

Blood (2014) 124 (21): 1754.

https://doi.org/10.1182/blood.V124.21.1754.1754

Published: 2014

Journal Articles

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

Blood (2010) 116 (14): 2438–2447.

https://doi.org/10.1182/blood-2010-03-275420

Published: 2010

Includes: Supplemental data

Journal Articles

Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma.

Bertram Glass, MD, PhD, Justin Hasenkamp, MD, Anke Goerlitz, Peter Dreger, Joerg Schubert, MD, Gerald Wulf, MD, Maike Nickelsen, Lorenz H. Truemper, MD, Norbert Schmitz

Blood (2009) 114 (22): 3379.

https://doi.org/10.1182/blood.V114.22.3379.3379

Published: 2009

Journal Articles

Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study.

Bertram Glass, MD, Justin Hasenkamp, MD, Anke Görlitz, Peter Dreger, MD, Jörg Schubert, MD, Gerald Wulf, MD, Maike Nickelsen, MD, Lorenz H. Truemper, MD, Norbert Schmitz, MD, PhD

Blood (2008) 112 (11): 1974.

https://doi.org/10.1182/blood.V112.11.1974.1974

Published: 2008

Journal Articles

Intermediate Intensity Conditioning Followed by Allogeneic Peripheral Blood Stem Cell Transplantion for Treatment of High Risk Relapse of Aggressive Lymphoma. Interim Analysis of the DSHNHL R3 Study.

Bertram Glass, MD, Justin Hasenkamp, MD, Peter Dreger, MD, Martin Gramatzki, MD, Joerg Schubert, MD, Gerald G. Wulf, MD, Maike Nickelsen, MD, Lorenz H. Truemper, MD, Norbert Schmitz, MD

Blood (2007) 110 (11): 3043.

https://doi.org/10.1182/blood.V110.11.3043.3043

Published: 2007

Journal Articles

Response to Re-Treatment with Rituximab Plus Salvage-Chemotherapy in Refractory or Relapsed Aggressive Non-Hodgkin’s Lymphoma.

Andrea Borgerding, Justin Hasenkamp, Bjoern Chapuy, Lorenz Truemper, Gerald Wulf, MD, PhD, Bertram Glass

Blood (2006) 108 (11): 4720.

https://doi.org/10.1182/blood.V108.11.4720.4720

Published: 2006

Journal Articles

Allo-Reactive NK Cells after HLA-Matched Allogeneic Hematopoietic Stem Cell Transplantation.

Justin Hasenkamp, Andrea Borgerding, Bjoern Chapuy, Gerald Wulf, PhD, MD, Inga Missal, Wolfram Jung, Lorenz Truemper, Bertram Glass

Blood (2006) 108 (11): 2904.

https://doi.org/10.1182/blood.V108.11.2904.2904

Published: 2006

Journal Articles

Prevention of Veno-Occlusive Disease in Hematopoietic Stem Cell Transplantation Due to Defibrotide Prophylaxis.

Justin Hasenkamp, MD, Imme Conradi, MD, Gerald Wulf, MD, PhD, Wolfram Jung, MD, Lorenz Truemper, MD, PhD, Bertram Glass, MD, PhD

Blood (2004) 104 (11): 1139.

https://doi.org/10.1182/blood.V104.11.1139.1139

Published: 2004

NARROW

Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

Results of the Astral Study: A Prospective Phase II Clinical Study of the German Lymphoma Alliance to Assess the Efficacy and Toxicity of High-Dose Chemotherapy Followed By Allogeneic Stem Cell Transplantation As Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Minimum Tolerable Interval of Radioimmunotherapy and Autologous Stem Cell Transplantation after High-Dose Chemotherapy for Relapsed or Refractory Aggressive B Cell Non-Hodgkin-Lymphoma Provides Excellent Disease Control

Combination of Lenalidomide and R-DHAP for Treatment of Relapsed and Refractory Aggressive B-NHL

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma.

Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study.

Intermediate Intensity Conditioning Followed by Allogeneic Peripheral Blood Stem Cell Transplantion for Treatment of High Risk Relapse of Aggressive Lymphoma. Interim Analysis of the DSHNHL R3 Study.

Response to Re-Treatment with Rituximab Plus Salvage-Chemotherapy in Refractory or Relapsed Aggressive Non-Hodgkin’s Lymphoma.

Allo-Reactive NK Cells after HLA-Matched Allogeneic Hematopoietic Stem Cell Transplantation.

Prevention of Veno-Occlusive Disease in Hematopoietic Stem Cell Transplantation Due to Defibrotide Prophylaxis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only